These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38772617)

  • 1.
    Cordier F; Creytens D
    J Clin Pathol; 2024 Jun; 77(7):435-438. PubMed ID: 38772617
    [No Abstract]   [Full Text] [Related]  

  • 2. The
    Berry JL; Polski A; Cavenee WK; Dryja TP; Murphree AL; Gallie BL
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31683923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acral fibromyxoma with loss of Rb1 by immunohistochemistry and fluorescence in situ hybridization: A diagnostically exploitable marker.
    Motanagh S; Bridge JA; Linos K
    J Cutan Pathol; 2021 Feb; 48(2):295-301. PubMed ID: 32524651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superficial acral fibromyxoma: clinicopathological, immunohistochemical, and molecular study of 11 cases highlighting frequent Rb1 loss/deletions.
    Agaimy A; Michal M; Giedl J; Hadravsky L; Michal M
    Hum Pathol; 2017 Feb; 60():192-198. PubMed ID: 27825811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RB1: a prototype tumor suppressor and an enigma.
    Dyson NJ
    Genes Dev; 2016 Jul; 30(13):1492-502. PubMed ID: 27401552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
    Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
    Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights into RB1 mutation.
    Yao Y; Gu X; Xu X; Ge S; Jia R
    Cancer Lett; 2022 Oct; 547():215870. PubMed ID: 35964818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
    Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
    Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
    Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating RB1 predictive value in clinical cancer therapy: Are we there yet?
    Indovina P; Pentimalli F; Conti D; Giordano A
    Biochem Pharmacol; 2019 Aug; 166():323-334. PubMed ID: 31176618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
    Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
    Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB1 5́UTR contains an IRES related to cell cycle control and cancer progression.
    Ma W; Ma B; Ma J; Zhu R
    Gene; 2023 Dec; 887():147724. PubMed ID: 37604323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
    Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
    Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
    Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
    Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.